MyFinsight
Home
Blog
About
Proceeds from maturities
of investments
$25,000K
(-66.44%↓ Y/Y)
Proceeds from issuance of
common stock under...
$7,299K
Proceeds from exercise of
common stock options
$8K
(700.00%↑ Y/Y)
Net cash provided by
investing activities
$14,947K
(-61.34%↓ Y/Y)
Net cash provided by
(used in) financing...
$7,269K
(1752.05%↑ Y/Y)
Canceled cashflow
$10,053K
Canceled cashflow
$38K
Net (decrease)
increase in cash, cash...
$7,354K
(253.56%↑ Y/Y)
Canceled cashflow
$14,862K
Purchases of investments
$9,966K
(-71.75%↓ Y/Y)
Purchases of property and
equipment
$87K
(-84.21%↓ Y/Y)
Stock-based compensation
expense
$2,214K
(-71.31%↓ Y/Y)
Accrued expenses and
other current...
$711K
(114.68%↑ Y/Y)
Depreciation expense
$405K
(-37.31%↓ Y/Y)
Non-cash operating lease
expense
$276K
(-45.13%↓ Y/Y)
Net amortization of
premiums and accretion of...
-$61K
(-111.44%↓ Y/Y)
Payments of tax
withholdings related to...
$34K
(-92.29%↓ Y/Y)
Payments of issuance
costs
$4K
Net cash used in
operating activities
-$14,862K
(58.88%↑ Y/Y)
Canceled cashflow
$3,667K
Net loss
-$17,964K
(55.85%↑ Y/Y)
Operating lease
liabilities
-$300K
(21.47%↑ Y/Y)
Accounts payable
-$214K
(-181.06%↓ Y/Y)
Prepaid expenses and
other current assets
$51K
(104.36%↑ Y/Y)
Back
Back
Cash Flow
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)
source: myfinsight.com